Sodium Chloride
Baxter Healthcare Corporation
Human Prescription Drug
NDC 0338-0050Sodium Chloride is a human prescription drug labeled by 'Baxter Healthcare Corporation'. National Drug Code (NDC) number for Sodium Chloride is 0338-0050. This drug is available in dosage form of Solution. The names of the active, medicinal ingredients in Sodium Chloride drug includes Sodium Chloride - 900 mg/100mL . The currest status of Sodium Chloride drug is Active.
Drug Information:
| Drug NDC: | 0338-0050 |
| The labeler code and product code segments of the National Drug Code number, separated by a hyphen. Asterisks are no longer used or included within the product code segment to indicate certain configurations of the NDC. |
| Proprietary Name: | Sodium Chloride |
| Also known as the trade name. It is the name of the product chosen by the labeler. |
| Product Type: | Human Prescription Drug |
| Indicates the type of product, such as Human Prescription Drug or Human OTC Drug. This data element corresponds to the “Document Type” of the SPL submission for the listing. |
| Non Proprietary Name: | Sodium Chloride |
| Also known as the generic name, this is usually the active ingredient(s) of the product. |
| Labeler Name: | Baxter Healthcare Corporation |
| Name of Company corresponding to the labeler code segment of the ProductNDC. |
| Dosage Form: | Solution |
| The translation of the DosageForm Code submitted by the firm. There is no standard, but values may include terms like `tablet` or `solution for injection`.The complete list of codes and translations can be found www.fda.gov/edrls under Structured Product Labeling Resources. |
| Status: | Active |
| FDA does not review and approve unfinished products. Therefore, all products in this file are considered unapproved. |
| Substance Name: | SODIUM CHLORIDE - 900 mg/100mL
|
| This is the active ingredient list. Each ingredient name is the preferred term of the UNII code submitted. |
| Route Details: | EXTRACORPOREAL
|
| The translation of the Route Code submitted by the firm, indicating route of administration. The complete list of codes and translations can be found at www.fda.gov/edrls under Structured Product Labeling Resources. |
Marketing Information:
An openfda section: An annotation with additional product identifiers, such as NUII and UPC, of the drug product, if available.
| Marketing Category: | NDA |
| Product types are broken down into several potential Marketing Categories, such as New Drug Application (NDA), Abbreviated New Drug Application (ANDA), BLA, OTC Monograph, or Unapproved Drug. One and only one Marketing Category may be chosen for a product, not all marketing categories are available to all product types. Currently, only final marketed product categories are included. The complete list of codes and translations can be found at www.fda.gov/edrls under Structured Product Labeling Resources. |
| Marketing Start Date: | 30 May, 1980 |
| This is the date that the labeler indicates was the start of its marketing of the drug product. |
| Marketing End Date: | 17 Jan, 2026 |
| This is the date the product will no longer be available on the market. If a product is no longer being manufactured, in most cases, the FDA recommends firms use the expiration date of the last lot produced as the EndMarketingDate, to reflect the potential for drug product to remain available after manufacturing has ceased. Products that are the subject of ongoing manufacturing will not ordinarily have any EndMarketingDate. Products with a value in the EndMarketingDate will be removed from the NDC Directory when the EndMarketingDate is reached. |
| Application Number: | NDA017867 |
| This corresponds to the NDA, ANDA, or BLA number reported by the labeler for products which have the corresponding Marketing Category designated. If the designated Marketing Category is OTC Monograph Final or OTC Monograph Not Final, then the Application number will be the CFR citation corresponding to the appropriate Monograph (e.g. “part 341”). For unapproved drugs, this field will be null. |
| Listing Expiration Date: | 31 Dec, 2023 |
| This is the date when the listing record will expire if not updated or certified by the firm. |
OpenFDA Information:
An openfda section: An annotation with additional product identifiers, such as NUII and UPC, of the drug product, if available.
| Manufacturer Name: | Baxter Healthcare Corporation
|
| Name of manufacturer or company that makes this drug product, corresponding to the labeler code segment of the NDC. |
| RxCUI: | 486515
|
| The RxNorm Concept Unique Identifier. RxCUI is a unique number that describes a semantic concept about the drug product, including its ingredients, strength, and dose forms. |
| Original Packager: | Yes
|
| Whether or not the drug has been repackaged for distribution. |
| UNII: | 451W47IQ8X
|
| Unique Ingredient Identifier, which is a non-proprietary, free, unique, unambiguous, non-semantic, alphanumeric identifier based on a substance’s molecular structure and/or descriptive information. |
| Pharmacologic Class: | Increased Large Intestinal Motility [PE]
Inhibition Large Intestine Fluid/Electrolyte Absorption [PE]
Osmotic Activity [MoA]
Osmotic Laxative [EPC]
|
| These are the reported pharmacological class categories corresponding to the SubstanceNames listed above. |
Packaging Information:
| Package NDC | Description | Marketing Start Date | Marketing End Date | Sample Available |
|---|
| 0338-0050-47 | 4 BAG in 1 CARTON (0338-0050-47) / 3000 mL in 1 BAG | 30 May, 1980 | N/A | No |
| Package NDC number, known as the NDC, identifies the labeler, product, and trade package size. The first segment, the labeler code, is assigned by the FDA. Description tells the size and type of packaging in sentence form. Multilevel packages will have the descriptions concatenated together. |
Product Elements:
Sodium chloride sodium chloride sodium chloride sodium cation chloride ion water
Indications and Usage:
Indications and usage 0.9% sodium chloride processing solution is indicated in processing blood cells. see directions accompanying blood cell processing device for complete instructions for use.
Warnings:
Warnings this container should not be connected for direct intravenous administration. the contents of an opened container should be used promptly to minimize the possibility of bacterial growth or pyrogen formation. discard the unused portion of processing solution.
Dosage and Administration:
Dosage and administration as directed by a physician. see directions accompanying blood cell processing device. processing solutions should be inspected visually for particulate matter and discoloration prior to use.
Contraindications:
Contraindications none known
Adverse Reactions:
Adverse reactions none known
Use in Pregnancy:
Pregnancy teratogenic effects pregnancy category c. animal reproduction studies have not been conducted with 0.9% sodium chloride processing solution. it is also not known whether 0.9% sodium chloride processing solution can cause fetal harm when administered to a pregnant woman or can affect reproduction capacity. 0.9% sodium chloride processing solution should be given to a pregnant woman only if clearly needed.
Pediatric Use:
Pediatric use safety and effectiveness in pediatric patients have not been established. do not administer unless solution is clear and seal is intact.
Description:
Description sodium chloride processing solution is a sterile, nonpyrogenic solution in single dose container for use in blood cell processing devices. it contains no antimicrobial agents. composition, osmolarity, ph, and ionic concentration are shown in table 1. table 1 0.9% sodium chloride processing solution size (ml) composition (g/l) osmolarity (mosmol/l) (calc) ph ionic concentration (meq/l) sodium chloride, usp (nacl) sodium chloride 3000 9 308 5.5 (4.5 to 7.0) 154 154 the plastic container is fabricated from a specially formulated polyvinyl chloride ( pl 146 plastic). the amount of water that can permeate from inside the container into the overwrap is insufficient to affect the solution significantly. solutions in contact with the plastic container can leach out certain of its chemical components in very small amounts within the expiration period, e.g., di-2-ethylhexylphthalate (dehp), up to 5 parts per million. however, the safety of the plastic has been confirmed in tests in animals according to usp biological tests for plastic containers as well as by tissue culture toxicity studies.
Clinical Pharmacology:
Clinical pharmacology 0.9% sodium chloride processing solution has value as a physiological blood cell processing aid.
How Supplied:
How supplied 0.9% sodium chloride processing solution in flexible plastic container is available as follows: code size (ml) ndc 2b7207 3000 0338-0050-47 exposure of pharmaceutical products to heat should be minimized. avoid excessive heat. it is recommended the product be stored at room temperature (25º c); brief exposure up to 40º c does not adversely affect the product. to open tear overwrap down side at slit and remove solution container. visually inspect the container. if the outlet port protector is damaged, detached, or not present, discard container as solution path sterility may be impaired. some opacity of the plastic due to moisture absorption during the sterilization process may be observed. this is normal and does not affect the solution quality or safety. the opacity will diminish gradually. check for minute leaks by squeezing inner bag firmly. if leaks are found, discard solution as sterility may be impaired. preparation for use 1. suspend container from eyelet supp
Read more...ort. 2. remove plastic protector from outlet port at bottom of container. 3. attach to blood cell processing device. refer to complete directions accompanying blood cell processing device.
Package Label Principal Display Panel:
Package/label principal display panel 3000 ml 2b7207 ndc 0338-0050-47 not for injection 0.9% sodium chloride processing solution each 100 ml contains 900 mg sodium chloride usp no antimicrobial agent has been added ph 5.5 (4.5 to 7.0) meq/l sodium 154 chloride 154 osmolarity 308 mosmol/l (calc) sterile nonpyrogenic single dose container dosage as directed by a physician see directions accompanying blood cell processing device for use this container should not be connected for direct intravenous administration cautions squeeze and inspect inner bag which maintains product sterility discard if leaks are found do not use unless solution is clear discard unused portion rx only store unit in moisture barrier overwrap at room temperature (25°c) until ready to use avoid excessive heat see insert 0.9% sodium chloride nacl processing solution viaflex container pl146 plastic for product information 1-800-933-0303 baxter logo baxter healthcare corporation deerfield, il 60015 usa made in usa baxter viaflex and pl 146 are trademarks of baxter international inc 2b7207 4-3000 ml plastic container 0.9% sodium chloride processing solution exp xxxxx secondary bar code (17) yymm00 (10) xxxxx lot xxxxx primary bar code (01) 50303380050470 sodium chloride representative container label sodium chloride representative carton label